Standard BioTools出售质谱流式业务并取得Illumina相关3000万美元买断款

Sale of Mass Cytometry Business to Multiplex Bio Ensures Full Continuity of CyTOF and Hyperion Product Lines, Customer Relationships, Dedicated Team and
Continued Investment
in Next Generation Multiplex Platforms
Receives Approximately
$30 Million
in Negotiated Buyout Related to Contingent Consideration Obligations From Illumina’s Acquisition of SomaLogic Business
BOSTON, Mass.
,
July 28, 2026
(GLOBE NEWSWIRE) --
Standard BioTools Inc.
(NASDAQ: LAB) ("Standard BioTools" or the "Company") today announced the following updates in connection with the Company’s previously announced merger with
Treeline Biosciences, Inc.
(“Treeline”):
Agreement to sell its Mass Cytometry business to Multiplex Bio, an entity founded and led by advanced imaging industry veterans,
Michael Johnson
, PhD,
Tom Villani
, PhD and
Charles Coffman
;
Buyout of the 2026 earnout and all future royalty payments for
$30 million
related to Illumina, Inc.’s previously completed acquisition of Standard BioTools’ SomaLogic business; and
Early termination of the waiting period by the
U.S. Federal Trade Commission
under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to the Treeline merger.
Sale of Mass Cytometry Business to Multiplex Bio
Multiplex Bio will be focused on the ongoing commercialization of Standard BioTools’ CyTOF and Hyperion product lines and investment in next generation multiplex platforms to advance scientific research. Multiplex Bio intends to maintain the full continuity of the business including all customer relationships, the majority of the Company’s Mass Cytometry team, existing service and maintenance commitments. The business will continue to operate under the
Standard BioTools
name and brand.
Dr. Johnson
will serve as Chief Executive Officer,
Dr. Villani
will serve as Chief Technology Officer and
Mr. Coffman
will serve as Chief Operating Officer of Multiplex Bio.
Dr. Johnson
and
Dr. Villani
co-founded Visikol, where they pioneered the commercialization of spatial biology tools including 3D microscopy, multiplex tissue imaging and digital pathology services for the world's leading pharmaceutical companies, building Visikol into a recognized leader in advanced tissue imaging before its acquisition by BICO in 2021. Mr. Coffman’s operational and financial background spans building and scaling life science businesses through periods of transition and growth.
Michael Egholm
, PhD, President and Chief Executive Officer of
Standard BioTools
, said, “Our Mass Cytometry technology, including the CyTOF and Hyperion instruments, provide unmatched multi-plexing capabilities for biomedical researchers studying a wide range of diseases. After a comprehensive evaluation of opportunities for this business, we are confident that Michael, Tom and Charles are uniquely positioned to steward our products and team given their scientific depth, commercial, operational experience and passion for the technology. Our products will continue to make a meaningful difference in single cell research and in the evolution of spatial biology.”
"The Standard BioTools Mass Cytometry business has an extraordinary scientific legacy and we are honored to carry it forward," said
Dr. Johnson
. "CyTOF and Hyperion have been foundational to the field of multiplex proteomic detection, and our goal is to build on that foundation and dedicate ourselves fully to advancing these platforms and supporting the scientists who depend on them every day. Our team has operated this technology firsthand and we understand deeply what it means to the customers and researchers who rely on it. We are genuinely excited by what lies ahead for this business and the broader field of multiplex proteomic imaging and detection where we strongly believe Standard BioTools’s products and team are positioned to lead the entire field."
The transaction is valued at up to
$10 million
, comprising a seller’s note issued by Multiplex Bio to
Standard BioTools
and a potential milestone payment.
Standard BioTools
has agreed to provide Multiplex Bio with a working capital loan of up to
$10 million
at the closing of the transaction.
The transaction is expected to close by the end of 2026, substantially concurrently with the closing of the Treeline transaction, subject to approval by Standard BioTools’ stockholders and other customary closing conditions.
Illumina Earnout and Royalty Buyout Payment
Standard BioTools
received approximately
$30 million
as a buyout of the 2026 earnout and all accrued and unpaid royalty payments related to Illumina, Inc.’s previously completed acquisition of Standard BioTools’ SomaLogic business. This payment will now be included in Standard BioTools’ pro forma net cash position at closing of the Treeline transaction, which will be used in determining the value of
Standard BioTools
in the exchange ratio in the Treeline transaction, in each case subject to the terms of the merger agreement with Treeline.
Pending Transaction with Treeline
On
July 20, 2026
,
Standard BioTools
filed its registration statement on Form S-4 with the U.S. Securities and Exchange Commission. On
July 21, 2026
, the
U.S. Federal Trade Commission
provided early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
The Company expects the Treeline transaction to close by the end of 2026, subject to approval by
Standard BioTools
stockholders and other customary closing conditions.
About Standard BioTools Inc.
Standard BioTools, Inc. (NASDAQ: LAB), is committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world class management team. The Company's established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster. Learn more at standardbio.com or connect with us on X, Facebook
®
, LinkedIn, and YouTube™.
For Research Use Only. Not for use in diagnostic procedures.
Limited Use Label License and other terms may apply:
standardbio.com/legal/terms-and-conditions/.
Patent and License Information:
standardbio.com/legal/notices
.
Trademarks:
standardbio.com/legal/trademarks
. Any other trademarks are the sole property of their respective owners. ©2026 Standard BioTools Inc.. All rights reserved.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the disposition of the Mass Cytometry business; the expected timing of the disposition of the Mass Cytometry business; the Treeline transaction; the expected timing of the closing of the Treeline transaction; the potential benefits of the Treeline transaction; the prospective performance and outlook of the combined company’s business, performance and opportunities; as well as any assumptions underlying any of the foregoing. The words “advance,” “build,” “lead,” “may,” “will,” “continue,” “commitment,” “expect,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks, uncertainties, and assumptions.
Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, risks and uncertainties related to: (i) the risk that the sale of the Mass Cytometry business may not be completed in a timely manner or at all; (ii) the ability to obtain the requisite approval for the sale of the Mass Cytometry business from stockholders of Standard BioTools; (iii) the possibility that any or all of the various conditions to the consummation of the sale of the Mass Cytometry business may not be satisfied or waived; (iv)